Point-of-care genetic testing: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
Traditional [[genetic testing]] involves the analysis of [[DNA]] in order to detect [[genotype]]s related to a heritable disease or [[phenotype]] of interest for clinical purposes. However, current testing methods require days to weeks before results are available limiting the clinical applicability of [[genetic testing]] in a number of circumstances. |
Traditional [[genetic testing]] involves the analysis of [[DNA]] in order to detect [[genotype]]s related to a heritable disease or [[phenotype]] of interest for clinical purposes. However, current testing methods require days to weeks before results are available limiting the clinical applicability of [[genetic testing]] in a number of circumstances. |
||
Recently, the first point-of-care genetic test in medicine was demonstrated to be effective in identifying CYP2C19*2 carriers allowing tailoring of anti-platelet regimens to reduce high on treatment platelet reactivity <ref>[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2960161-5/abstract#]</ref>. Drs. Jason Roberts and Derek So from the [[University of Ottawa Heart Institute]] validated a [[pharmacogenomics]] approach in patients undergoing [[percutaneous coronary intervention]] for [[acute coronary syndrome]] or stable [[coronary artery disease]]. |
Recently, the first point-of-care genetic test in medicine was demonstrated to be effective in identifying CYP2C19*2 carriers allowing tailoring of anti-platelet regimens to reduce high on treatment platelet reactivity <ref>[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2960161-5/abstract#]</ref>. Drs. Jason Roberts and Derek So from the [[University of Ottawa Heart Institute]] validated a [[pharmacogenomics]] approach in patients undergoing [[percutaneous coronary intervention]] for [[acute coronary syndrome]] or stable [[coronary artery disease]] <<ref>>[http://www.winnipegfreepress.com/arts-and-life/life/health/first-bedside-gene-test-shows-promise-144912695.html]</ref>. |
||
This study is the first in medicine to incorporate [[point-of-care testing]] with [[genetics]] into routine clinical care and decision making. |
This study is the first in medicine to incorporate [[point-of-care testing]] with [[genetics]] into routine clinical care and decision making. |
||
Revision as of 18:04, 12 April 2012
Point-of-care genetic testing incorporates the newest most sophisticated techniques to identify variations in the genetic sequence at the bedside – enabling clinicians to react and alter therapy based upon the results.
Traditional genetic testing involves the analysis of DNA in order to detect genotypes related to a heritable disease or phenotype of interest for clinical purposes. However, current testing methods require days to weeks before results are available limiting the clinical applicability of genetic testing in a number of circumstances.
Recently, the first point-of-care genetic test in medicine was demonstrated to be effective in identifying CYP2C19*2 carriers allowing tailoring of anti-platelet regimens to reduce high on treatment platelet reactivity [1]. Drs. Jason Roberts and Derek So from the University of Ottawa Heart Institute validated a pharmacogenomics approach in patients undergoing percutaneous coronary intervention for acute coronary syndrome or stable coronary artery disease <[2].
This study is the first in medicine to incorporate point-of-care testing with genetics into routine clinical care and decision making.